stars 1 stars 2 stars 3

Oxford StemTech is advancing drug discovery and precision medicine through human stem cell technologies. An Oxford University spinout, Oxford StemTech develops and delivers advanced human induced pluripotent stem cell (iPSC) models and assay platforms to accelerate disease research, drug target discovery, and therapeutic development. Our capabilities span the entire iPSC workflow, from scalable reprogramming and genome engineering to directed differentiation, complex 3D organoids and assembloids, and functional phenotyping. We specialise in generating disease-relevant human cellular models, including neurons, microglia, macrophages and oligodendrocytes, supported by advanced technologies such as multi-electrode array (MEA) electrophysiology, high-content imaging and molecular profiling. By combining patient-specific stem cell models with scalable functional assays, we enable researchers and pharmaceutical companies to investigate disease mechanisms, identify and validate drug targets and evaluate therapeutic efficacy. Our ambition is to bridge the gap between conventional preclinical models and human biology, enabling drug discovery across genetically diverse patient populations and supporting the development of more effective, personalised medicines. From patient-derived cells to actionable insights for drug discovery and precision medicine.

Oxford StemTech Questions

Galbha Duggal is the Chief Scientific Officer, Co-Founder of Oxford StemTech.

6 people are employed at Oxford StemTech.

Top Oxford StemTech Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users